A Study of CAR-T Cells in Subjects With Autoimmune Diseases
NCT07040917 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2025-07-20
Summary
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in Subjects with autoimmune diseases.
Conditions
Interventions
- DRUG
-
CAR-T cell
CAR-T cell
Sponsors & Collaborators
-
Chinese PLA General Hospital
lead OTHER
Principal Investigators
-
Jian Zhu · Chinese PLA General Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-30
- Primary Completion
- 2027-11-30
- Completion
- 2028-04-30
Countries
- China
Study Locations
More Related Trials
-
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
NCT06821659 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT06548607 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
CAR-T Cells Therapy for Patients With Autoimmune Diseases
NCT07052565 ·Status: RECRUITING ·Phase: NA
-
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
NCT07212322 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
NCT06549296 ·Status: SUSPENDED ·Phase: EARLY_PHASE1
-
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
NCT06775912 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
NCT07203404 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06983964 ·Status: RECRUITING ·Phase: NA
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT07161193 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT06794008 ·Status: RECRUITING ·Phase: PHASE2
-
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
NCT06373081 ·Status: RECRUITING ·Phase: NA
-
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease
NCT07193667 ·Status: RECRUITING ·Phase: NA
-
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
NCT06485232 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
NCT06316076 ·Status: RECRUITING ·Phase: PHASE1
-
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
NCT06420154 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
NCT06939166 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
NCT03638206 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
NCT06056921 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
NCT07301164 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
NCT06503224 ·Status: RECRUITING ·Phase: NA
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT06688799 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
NCT06279923 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
NCT06435897 ·Status: RECRUITING ·Phase: PHASE1/PHASE2